Steven Cohn

View Scopus Profile

Emailsmcohnutmbedu

h-index

Research activity per year

If you made any changes in Pure these will be visible here soon.

Research Strategic Pillar Keywords

Specialized Health

Fingerprint

Dive into the research topics where Steven Cohn is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

1 Similar Profiles

2 Completed
7 Active

A Phase 3 Study to Evaluate the Efficacy and Long-term Safety of SHR0302 for Induction, Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis.
Cohn, S.
1/19/22 → 1/18/27
Project: Other project
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active Controlled, Treat-Through study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn's Disease
Cohn, S.
8/20/20 → 8/19/22
Project: Other project
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active Controlled, Treat-Through study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn's Disease
Cohn, S.
Eli Lilly
8/20/20 → 8/19/22
Project: Other project
Protocol I6T-MC-AMBG (a) A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis - LUCENT 2
Cohn, S.
Eli Lilly & Company
5/13/20 → 5/12/25
Project: Other project
Protocol I6T-MC-AMBG (a) A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis - LUCENT 2
Cohn, S.
5/13/20 → 5/12/25
Project: Other project

41 Article
2 Chapter
1 Review article

GPR120 Inhibits Colitis Through Regulation of CD4⁺ T Cell Interleukin 10 Production
Yang, W., Liu, H., Xu, L., Yu, T., Zhao, X., Yao, S., Zhao, Q., Barnes, S., Cohn, S. M., Dann, S. M., Zhang, H., Zuo, X., Li, Y. & Cong, Y., Jan 2022, In: Gastroenterology. 162, 1, p. 150-165 16 p.
Research output: Contribution to journal › Article › peer-review
3 Scopus citations
AIDS-associated Esophageal Plasmablastic Lymphoma
Abdulla, H. M. & Cohn, S., Jan 2021, In: Clinical Gastroenterology and Hepatology. 19, 1, p. A18
Research output: Contribution to journal › Article › peer-review

1 Scopus citations
Restarting elective endoscopy safely amidst an evolving pandemic and the impact of patient perception
Nguyen, C., Kline, K. T., Merwat, S., Merwat, S., Luthra, G., Parupudi, S. & Cohn, S., Dec 2021, In: BMC Gastroenterology. 21, 1, 344.
Research output: Contribution to journal › Article › peer-review

Open Access
Fibroblast growth factor receptor-3 (FGFR-3) regulates expression of paneth cell lineage-specific genes in intestinal epithelial cells through both TCF4/β-catenin-dependent and -independent signaling pathways
Brodrick, B., Vidrich, A., Porter, E., Bradley, L., Buzan, J. M. & Cohn, S. M., May 27 2011, In: Journal of Biological Chemistry. 286, 21, p. 18515-18525 11 p.
Research output: Contribution to journal › Article › peer-review
19 Scopus citations
Colitis causes delay in puberty in female mice out of proportion to changes in leptin and corticosterone
DeBoer, M. D., Li, Y. & Cohn, S., Mar 2010, In: Journal of Gastroenterology. 45, 3, p. 277-284 8 p.
Research output: Contribution to journal › Article › peer-review
28 Scopus citations

Steven Cohn, MD, PhD, AGAF, FACG

Personal profile

Research Strategic Pillar Keywords

Fingerprint

Network

Dive into details

A Phase 3 Study to Evaluate the Efficacy and Long-term Safety of SHR0302 for Induction, Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis.

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active Controlled, Treat-Through study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn's Disease

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active Controlled, Treat-Through study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn's Disease

Protocol I6T-MC-AMBG (a) A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis - LUCENT 2

Protocol I6T-MC-AMBG (a) A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis - LUCENT 2

GPR120 Inhibits Colitis Through Regulation of CD4⁺ T Cell Interleukin 10 Production

AIDS-associated Esophageal Plasmablastic Lymphoma

Restarting elective endoscopy safely amidst an evolving pandemic and the impact of patient perception

Fibroblast growth factor receptor-3 (FGFR-3) regulates expression of paneth cell lineage-specific genes in intestinal epithelial cells through both TCF4/β-catenin-dependent and -independent signaling pathways

Colitis causes delay in puberty in female mice out of proportion to changes in leptin and corticosterone

Steven Cohn, MD, PhD, AGAF, FACG

Personal profile

Research Strategic Pillar Keywords

Fingerprint

Network

Projects

Research output